Weekly Investment Analysts’ Ratings Updates for Charles River Laboratories Intl. (CRL)

Share on StockTwits

Charles River Laboratories Intl. (NYSE: CRL) recently received a number of ratings updates from brokerages and research firms:

  • 8/28/2018 – Charles River Laboratories Intl. was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/27/2018 – Charles River Laboratories Intl. had its price target raised by analysts at Argus from $125.00 to $140.00. They now have a “buy” rating on the stock.
  • 8/23/2018 – Charles River Laboratories Intl. was upgraded by analysts at Raymond James from a “market perform” rating to an “outperform” rating. They now have a $140.00 price target on the stock.
  • 8/21/2018 – Charles River Laboratories Intl. had its price target lowered by analysts at Credit Suisse Group AG from $129.00 to $121.00. They now have a “neutral” rating on the stock.
  • 8/9/2018 – Charles River Laboratories Intl. had its price target raised by analysts at Barclays PLC from $110.00 to $120.00. They now have an “equal weight” rating on the stock.
  • 8/9/2018 – Charles River Laboratories Intl. had its price target raised by analysts at Jefferies Financial Group Inc from $140.00 to $145.00. They now have a “buy” rating on the stock.
  • 8/9/2018 – Charles River Laboratories Intl. had its price target raised by analysts at SunTrust Banks, Inc. to $135.00. They now have a “buy” rating on the stock.
  • 7/20/2018 – Charles River Laboratories Intl. had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc. They now have a $140.00 price target on the stock.
  • 7/18/2018 – Charles River Laboratories Intl. was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 7/17/2018 – Charles River Laboratories Intl. was upgraded by analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating. They now have a $131.00 price target on the stock.
  • 7/16/2018 – Charles River Laboratories Intl. had its price target raised by analysts at Bank of America Corp from $120.00 to $125.00. They now have a “buy” rating on the stock.

NYSE CRL traded up $0.82 on Friday, hitting $126.32. 325,387 shares of the stock were exchanged, compared to its average volume of 369,654. Charles River Laboratories Intl. Inc has a 52-week low of $96.70 and a 52-week high of $130.66. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.48 and a current ratio of 1.72. The stock has a market cap of $5.97 billion, a price-to-earnings ratio of 23.97, a PEG ratio of 1.57 and a beta of 0.65.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 8th. The medical research company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The firm had revenue of $585.30 million for the quarter, compared to analysts’ expectations of $570.65 million. During the same period in the previous year, the company posted $1.29 EPS. The company’s quarterly revenue was up 24.8% compared to the same quarter last year. research analysts forecast that Charles River Laboratories Intl. Inc will post 5.88 EPS for the current fiscal year.

In other Charles River Laboratories Intl. news, insider Birgit Girshick sold 3,978 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Tuesday, July 17th. The shares were sold at an average price of $119.90, for a total transaction of $476,962.20. Following the transaction, the insider now directly owns 18,999 shares in the company, valued at approximately $2,277,980.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO James C. Foster sold 5,005 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $110.80, for a total transaction of $554,554.00. Following the transaction, the chief executive officer now owns 296,676 shares in the company, valued at $32,871,700.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,324 shares of company stock worth $4,504,045. Corporate insiders own 2.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in shares of Charles River Laboratories Intl. by 423.6% during the 1st quarter. Wells Fargo & Company MN now owns 1,249,196 shares of the medical research company’s stock valued at $133,339,000 after buying an additional 1,010,618 shares during the period. BlackRock Inc. boosted its stake in shares of Charles River Laboratories Intl. by 7.0% during the 2nd quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock valued at $499,216,000 after buying an additional 292,685 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Charles River Laboratories Intl. by 99.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 261,857 shares of the medical research company’s stock valued at $29,396,000 after buying an additional 130,325 shares during the period. Massachusetts Financial Services Co. MA acquired a new stake in shares of Charles River Laboratories Intl. during the 1st quarter valued at $13,139,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Charles River Laboratories Intl. by 26.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 382,582 shares of the medical research company’s stock valued at $42,949,000 after buying an additional 80,519 shares during the period. Hedge funds and other institutional investors own 97.76% of the company’s stock.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Fundamental Analysis and Individual Investors

Receive News & Ratings for Charles River Laboratories Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply